Immunoglobulin M Monoclonal Gammopathies of Clinical Significance
- PMID: 35756635
- PMCID: PMC9219578
- DOI: 10.3389/fonc.2022.905484
Immunoglobulin M Monoclonal Gammopathies of Clinical Significance
Abstract
Immunoglobulin M monoclonal gammopathy of undetermined significance (MGUS) comprises 15-20% of all cases of MGUS. IgM MGUS is distinct from other forms of MGUS in that the typical primary progression events include Waldenstrom macroglobulinaemia and light chain amyloidosis. Owing to its large pentameric structure, IgM molecules have high intrinsic viscosity and precipitate more readily than other immunoglobulin subtypes. They are also more commonly associated with autoimmune phenomena, resulting in unique clinical manifestations. Organ damage attributable to the paraprotein, not fulfilling criteria for a lymphoid or plasma cell malignancy has recently been termed monoclonal gammopathy of clinical significance (MGCS) and encompasses an important family of disorders for which diagnostic and treatment algorithms are evolving. IgM related MGCS include unique entities such as cold haemagglutinin disease, IgM related neuropathies, renal manifestations and Schnitzler's syndrome. The diagnostic approach to, and management of these disorders differs significantly from other categories of MGCS. We describe a practical approach to the evaluation of these patients and our approach to their treatment. We will also elaborate on the key unmet needs in IgM MGCS and highlight potential areas for future research.
Keywords: MGRS; immunoglobulin M; monoclonal gammopathy of clinical significance (MGCS); monoclonal gammopathy of neurological significance; monoclonal gammopathy of undetermined significance.
Copyright © 2022 Girard, Soekojo, Ooi, Chng and de Mel.
Conflict of interest statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Figures
References
-
- Bird J, Behrens J, Westin J, Turesson I, Drayson M, Beetham R, et al. . UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): Guidelines for the Investigation of Newly Detected M-Proteins and the Management of Monoclonal Gammopathy of Undetermined Significance (MGUS). Br J Haematol (2009) 147:22–42. doi: 10.1111/j.1365-2141.2009.07807.x - DOI - PubMed
-
- Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. . Monoclonal Gammopathy of Undetermined Significance (MGUS) and Smoldering (Asymptomatic) Multiple Myeloma: IMWG Consensus Perspectives Risk Factors for Progression and Guidelines for Monitoring and Management. Leukemia (2010) 24:1121–7. doi: 10.1038/leu.2010.60 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
